Team will present posters including 2 on ioCRISPR-Ready Cells & host an expert panel discussion on the important role of functional genomics in early drug discovery.
30.01.2024
ioCells™️ range expands with early access launch of ioMotor Neurons™️
Product will provide robust, standardised tool for study and screening of potential treatments for motor neuron diseases.
UK Science Minister Andrew Griffith MP opens bit.bio expanded labs
Minister Griffith cut the ribbon to officially open bit.bio’s manufacturing and automation labs for the consistent and scalable pr...
New collaboration to develop multi-cell models of the human brain
King's College London & bit.bio collaborate to develop multi-cell models of the human brain with optimised open-source protocols f...
bit.bio CEO wins in 2 categories at Great British Entrepreneur Awards
Mark Kotter wins in two categories, Equity-Backed Entrepreneur of the Year and Purpose Entrepreneur of the Year, at the Great Brit...
bit.bio unveils cell therapy pipeline, lead candidate and expanded SAB
Lead candidate is encapsulated allogeneic txHepatocytes for treatment of acute liver failure, SAB expanded to include 3 global exp...
Product launch | CRISPR-Ready ioGlutamatergic Neurons
bit.bio launches first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease m...
Synthego and bit.bio expand strategic partnership
Partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therap...
BlueRock Therapeutics and bit.bio announce collaboration
BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery & manufacture of regulatory T cell...